RxDoctor Payments Data

Taylore Kusel, APRN

Family · Owasso, OKNPI 1598437097

Payments from drug & device makers

$1,888in general payments, 2019–2025

Across 113 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$867
  • AbbVie$474
  • Lilly USA, LLC$101
  • Boehringer Ingelheim$93
  • Astellas Pharma US Inc$60
  • Sumitomo Pharma America, Inc.$53
  • plus $240 from 10 others

What the payments were for

  • Food & beverage$1,888100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,888 in reported general payments places this provider in the 80th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$49,869
Medicare patients
163
Services billed
941

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide73$75,830
OzempicSemaglutide41$43,011
JardianceEmpagliflozin40$42,311
TrulicityDulaglutide30$38,473
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$23,319
EliquisApixaban29$21,357
RybelsusSemaglutide14$17,600
XareltoRivaroxaban15$11,102
JanuviaSitagliptin Phosphate13$9,259
TradjentaLinagliptin19$7,472
Breo ElliptaFluticasone/Vilanterol12$4,805
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$2,648
Gabapentin192$2,482
Omeprazole142$2,099
Atorvastatin Calcium181$1,715

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$101$114,304103 claims
Novo NordiskOzempic, Rybelsus$867$60,61155 claims
Boehringer IngelheimJardiance, Tradjenta$93$49,78359 claims
GSKTrelegy Ellipta, Breo Ellipta$18$28,12340 claims
PfizerEliquis$50$21,35729 claims
Johnson & JohnsonXarelto$12$11,10215 claims
AbbVieSynthroid$474$92711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,026 family providers in Oklahoma.

Other family in Owasso

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →